Sanofi (NASDAQ:SNY) Posts Earnings Results, Beats Estimates By $0.10 EPS

Sanofi (NASDAQ:SNY) posted its quarterly earnings results on Friday. The company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.60 by $0.10, Zacks reports. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The firm had revenue of $14.53 billion during the quarter, compared to analyst estimates of $12.62 billion. During the same quarter in the prior year, the business posted $2.25 earnings per share. The company’s quarterly revenue was down 7.5% compared to the same quarter last year.

Sanofi Price Performance

Shares of SNY stock opened at $51.64 on Friday. Sanofi has a 52-week low of $44.62 and a 52-week high of $60.12. The stock has a market cap of $126.80 billion, a PE ratio of 12.09, a PEG ratio of 1.25 and a beta of 0.51. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27. The firm’s 50 day moving average price is $48.65 and its two-hundred day moving average price is $49.55.

Institutional Investors Weigh In On Sanofi

Several hedge funds have recently bought and sold shares of SNY. Brighton Jones LLC raised its holdings in Sanofi by 52.6% in the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company’s stock worth $261,000 after purchasing an additional 1,869 shares during the period. AQR Capital Management LLC raised its holdings in Sanofi by 107.2% in the first quarter. AQR Capital Management LLC now owns 30,518 shares of the company’s stock worth $1,693,000 after purchasing an additional 15,791 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Sanofi by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,255 shares of the company’s stock worth $2,732,000 after purchasing an additional 752 shares during the period. Sivia Capital Partners LLC raised its holdings in Sanofi by 5.4% in the second quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company’s stock worth $326,000 after purchasing an additional 347 shares during the period. Finally, EverSource Wealth Advisors LLC raised its holdings in Sanofi by 36.1% in the second quarter. EverSource Wealth Advisors LLC now owns 3,301 shares of the company’s stock worth $159,000 after purchasing an additional 875 shares during the period. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts recently issued reports on SNY shares. Barclays reissued an “overweight” rating on shares of Sanofi in a research report on Wednesday, July 2nd. Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $56.00 to $58.00 in a research report on Monday, September 8th. JPMorgan Chase & Co. raised shares of Sanofi from a “neutral” rating to an “overweight” rating in a research report on Friday, August 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, Sanofi presently has a consensus rating of “Buy” and a consensus price target of $62.67.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.